Canopy Growth Corporation (CGC) Stock Price & Analysis

Canopy Growth Corporation (CGC) is trading at USD 0.67, down 0.01% today, as of October 23, 2026 at 17:00 UTC (US market open; quotes may be delayed), according to Nexqual market data.

CGC last closed at USD 0.67; today's session has ranged USD 0.65–0.68 on volume of 1,435,723 shares. Market capitalization is —, with a 52-week range of USD 0.65–2.38 (NMS). Source: Nexqual, retrieved October 23, 2026 at 17:01 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CGC.md

Key facts (CGC)

• Insider open-market sales, last ~7 months: 14 Form 4 filings, $326K; 14 not under a Rule 10b5-1 plan ($326K); 0 by opportunistic insiders, 4 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Total return with dividends: 1Y -49.6% vs S&P 500 +14.6%; 5Y -99.5% vs S&P 500 +77.3%.
• Next earnings: 2026-11-06, EPS estimate USD -0.03, revenue estimate $82.5M.

Insider sales (SEC Form 4, open-market, last ~7 months) (CGC)

0 of 14 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Total return (dividends reinvested) (CGC)

CGC revenue by business segment (quarter ended Jun 30, 2026)

CGC revenue by product line (quarter ended Jun 30, 2026)

CGC revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

CGC suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Jun 15, 2026.

CGC analyst estimates and revisions

CGC options: expected move

Options price a move of about ±37.6% (±$0.25) by Nov 6, 2026, which includes earnings on Nov 6, 2026. Over the last 8 reports the stock moved ±18% on average.

30-day implied volatility 79.4% vs 45.2% realized over the last 30 trading days. Put/call ratio (volume) 0.21. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 17:01 UTC)

Technical Analysis (CGC)

Nexqual's technical model rates CGC "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 17:01 UTC.

Earnings (CGC)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 17:01 UTC.

Financials & Fundamentals (CGC)

Source: Nexqual, October 23, 2026 at 17:01 UTC.

Ownership (CGC)

Source: Nexqual, October 23, 2026 at 17:01 UTC.

From Canopy Growth Corporation's Latest SEC 10-K Filing (filed 2026-06-15)

Key Strengths & Strategy (as disclosed to the SEC)

• As the leaders in providers of medical cannabis to patients in Canada, our award-winning network of clinics allows us to serve patients nationwide across the Apollo, Canada House and Abba Medix banners.
• Our diverse brand portfolio enables us to effectively reach a broad spectrum of consumers for a variety of needs and occasions throughout their day – whether for adult-use or for medical purposes.
• We have developed several programs to improve access to medical cannabis for authorized patients.
• Further, the receipt of EU-GMP certification at the Kincardine facility enables us to continue exporting certified medical cannabis to medical markets in Europe and Australia.

Partnerships

• Following the first anniversary of the first interest payment date, each Lender will have the option to require the borrowers to repay such Lender its pro rata share of up to US$3.0 million of principal per calendar month on each payment date thereafter.
• In connection with the Loan Agreement, on the Loan Closing Date, the Company issued 18,705,578 common share purchase warrants of the Company (the "Loan Warrants") to the Lenders in accordance with each Lender's pro rata share of the Loans.

Legal & Regulatory Risks (Item 1A, quoted)

• We operate in highly regulated industries where the regulatory environments are rapidly developing and we may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business.
• The regulatory environment for our products is rapidly developing, and the need to build and maintain robust systems to comply with different and changing regulations in multiple jurisdictions increases the possibility that we may violate one or more applicable requirements.
• Changes in the laws, regulations and guidelines governing cannabis and hemp may adversely affect our business and that of our investments.
• We are subject to certain restrictions of the TSX and Nasdaq, which may constrain our ability to expand our business in the United States.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 17:01 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt